Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SUPN
stocks logo

SUPN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
195.48M
+12.24%
0.437
-20.36%
192.18M
+28.27%
0.445
+1.99%
208.85M
+26.23%
0.725
-19.95%
Estimates Revision
The market is revising Upward the revenue expectations for Supernus Pharmaceuticals, Inc. (SUPN) for FY2025, with the revenue forecasts being adjusted by 1.92% over the past three months. During the same period, the stock price has changed by -1.96%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+74.77%
In Past 3 Month
Stock Price
Go Down
down Image
-1.96%
In Past 3 Month
Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is 60.50 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is 60.50 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 45.100
sliders
Low
50.00
Averages
60.50
High
65.00
Current: 45.100
sliders
Low
50.00
Averages
60.50
High
65.00
BofA
initiated
$65
2025-10-29
Reason
BofA
Price Target
$65
2025-10-29
initiated
Reason
BofA initiated coverage of Supernus with a Buy rating and $65 price target, citing what it sees as the "underappreciated" branded central nervous system growth drivers with its treatments for ADHD and motor complications in advanced Parkinson's disease. Qelbree offers a differentiated non-stimulant that continues to capture share both from patients new to treatment and those switching from other therapies, while Onapgo has "impressed" in its first quarter on the market, the analyst tells investors.
TD Cowen
TD Cowen
Buy
upgrade
$45 -> $60
2025-10-23
Reason
TD Cowen
TD Cowen
Price Target
$45 -> $60
2025-10-23
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Supernus to $60 from $45 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results. They said Onapgo's initial adoption is exceeding expectations, and expect sales of $8MM in Q3 and $23MM for 2025 which could be potentially conservative. Qelbree adoption is progressing well, and raised its 2025 sales estimate to $310MM. Zurzuvae to add to solid ongoing launches.
Cantor Fitzgerald
Overweight
maintain
$46 -> $63
2025-09-30
Reason
Cantor Fitzgerald
Price Target
$46 -> $63
2025-09-30
maintain
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Supernus to $63 from $46 and keeps an Overweight rating on the shares. The firm updated its model for ONAPGO to factor in a faster cadence of patients on therapy that slightly increases its peak sales potential. Cantor believes there may be even more upside beyond its ONAPGO estimates at this time, the analyst tells investors in a research note.
Piper Sandler
Neutral
maintain
$36 -> $40
2025-08-29
Reason
Piper Sandler
Price Target
$36 -> $40
2025-08-29
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Supernus to $40 from $36 and keeps a Neutral rating on the shares. Though the firm does wonder if there is more room for multiple expansion given the company's longer-term LOE exposure, Piper does concede that Onapgo, an infusion pump that provides continuous subcutaneous delivery of apomorphine for patients with advanced Parkinson's disease, is off to a strong start and bears watching as an upside driver.
Cantor Fitzgerald
Neutral -> Overweight
upgrade
$36 -> $42
2025-07-29
Reason
Cantor Fitzgerald
Price Target
$36 -> $42
2025-07-29
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald upgraded Supernus to Overweight from Neutral with a price target of $42, up from $36.
Cantor Fitzgerald
Kristen Kluska
Neutral -> Overweight
upgrade
$36 -> $42
2025-07-29
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$36 -> $42
2025-07-29
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald analyst Kristen Kluska upgraded Supernus to Overweight from Neutral with a price target of $42, up from $36. The firm believes Qelbree is redefining the treatment landscape for attention-deficit/hyperactivity disorder. The analyst cites a more positive outlook on Qelbree following its 25 physician survey for the upgrade. Cantor says 72% of those surveyed indicated they plan to prescribe more non-stimulants in the future, and it believes Qelbree could be a big part of this growth.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN.O) is 17.54, compared to its 5-year average forward P/E of 21.48. For a more detailed relative valuation and DCF analysis to assess Supernus Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
21.48
Current PE
17.54
Overvalued PE
27.36
Undervalued PE
15.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.38
Undervalued EV/EBITDA
7.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.79
Current PS
0.00
Overvalued PS
3.18
Undervalued PS
2.41
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 146.58% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SUPN News & Events

Events Timeline

(ET)
2025-11-04
17:32:09
Supernus increases FY25 revenue forecast to $685M-$705M, up from $670M-$700M
select
2025-11-04
17:30:23
Supernus announces Q3 earnings per share of 80 cents, up from 69 cents last year.
select
2025-08-05 (ET)
2025-08-05
16:35:41
Supernus reports Q2 EPS 40c vs. 36c last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
12-01TipRanks
Bank of America Identifies Five Stocks with Strong Growth Potential for 2025

  • Bank of America's Stock Picks: Bank of America has identified a list of stocks across various sectors, including tech, finance, health, and industry, that are expected to perform well for the remainder of the year, based on strong sales trends and client growth.

  • Nvidia's Strong Performance: Nvidia remains a top pick for the bank, with a Buy rating maintained after reporting $57 billion in revenue, driven by high demand for AI components, and an expected earnings per share growth of over 40% in the next year.

  • Palantir's Client Growth: Palantir's price target was raised significantly due to a 45% increase in total clients and a 65% rise in U.S. commercial clients, highlighting its capabilities in secure AI tools and potential for future contracts.

  • Positive Outlook for Other Stocks: Bank of America also supports Robinhood, Crane, and Supernus Pharmaceuticals, citing strong revenue growth, stable market performance, and promising drug developments as key factors for their positive ratings and price target increases.

[object Object]
Preview
9.0
11-25Yahoo Finance
Evaluating Supernus Pharmaceuticals Following FDA Pipeline Update and 24% Surge in 2025

  • Stock Performance: Supernus Pharmaceuticals has seen a 0.5% increase over the past week, recovering from a 14.2% drop in the last month, and has gained 24.4% year-to-date and 25.5% over the past year.

  • Valuation Insights: The company is currently considered undervalued, with a Discounted Cash Flow (DCF) analysis suggesting an 82.0% discount to its intrinsic value of $252.45 per share.

  • Price-to-Sales Ratio: Supernus trades at a P/S ratio of 3.81x, which is below the industry average of 4.03x, indicating it may be undervalued compared to its peers.

  • Narrative Approach: Investors can utilize personalized Narratives to assess Supernus Pharmaceuticals, which incorporate individual assumptions about future performance, allowing for a more dynamic understanding of the stock's fair value.

[object Object]
Preview
2.0
10-31NASDAQ.COM
Biotech Stocks Reach 52-Week Peaks: MTSR, INSM, ABVX, and MAZE Drive Surge on October 30

  • Biotech Market Surge: On October 30, 2025, numerous biopharma stocks reached new 52-week highs due to breakthrough trial data, strategic deals, and earnings surprises, indicating strong investor confidence in the sector.

  • Metsera Inc. Developments: Metsera's positive Phase 2b results for its obesity treatment MET-097i and an unsolicited $9 billion acquisition proposal from Novo Nordisk highlight its potential, while ongoing trials are set to advance in 2026.

  • Indivior and Insmed Performance: Indivior reported a significant increase in net income and revenue, while Insmed raised its revenue guidance for ARIKAYCE, showcasing strong financial performance in the biopharmaceutical space.

  • Emerging Biotech Innovations: Companies like Ventyx, Inhibrx, and Arrowhead are making strides with promising trial results and strategic partnerships, reflecting a dynamic landscape in biotech focused on addressing various health challenges.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Supernus Pharmaceuticals Inc (SUPN) stock price today?

The current price of SUPN is 45.1 USD — it has increased 0.76 % in the last trading day.

arrow icon

What is Supernus Pharmaceuticals Inc (SUPN)'s business?

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

arrow icon

What is the price predicton of SUPN Stock?

Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is 60.50 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Supernus Pharmaceuticals Inc (SUPN)'s revenue for the last quarter?

Supernus Pharmaceuticals Inc revenue for the last quarter amounts to 192.10M USD, increased 9.34 % YoY.

arrow icon

What is Supernus Pharmaceuticals Inc (SUPN)'s earnings per share (EPS) for the last quarter?

Supernus Pharmaceuticals Inc. EPS for the last quarter amounts to -0.80 USD, decreased -215.94 % YoY.

arrow icon

What changes have occurred in the market's expectations for Supernus Pharmaceuticals Inc (SUPN)'s fundamentals?

The market is revising Upward the revenue expectations for Supernus Pharmaceuticals, Inc. (SUPN) for FY2025, with the revenue forecasts being adjusted by 1.92% over the past three months. During the same period, the stock price has changed by -1.96%.
arrow icon

How many employees does Supernus Pharmaceuticals Inc (SUPN). have?

Supernus Pharmaceuticals Inc (SUPN) has 674 emplpoyees as of December 05 2025.

arrow icon

What is Supernus Pharmaceuticals Inc (SUPN) market cap?

Today SUPN has the market capitalization of 2.59B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free